The SHIP‐1 activator (AQX‐1125) used in clinical trials in chronic obstructive pulmonary disease (COPD) and allergic asthma demonstrated a favourable safety profile and anti‐inflammatory activity (trial number: NCT01954628). The gene discussed is INPP5D; the disease is chronic obstructive pulmonary disease.